|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012634,
umls-concept:C0026336,
umls-concept:C0030956,
umls-concept:C0155877,
umls-concept:C0243071,
umls-concept:C0302350,
umls-concept:C0591833,
umls-concept:C0868945,
umls-concept:C0871261,
umls-concept:C1423842,
umls-concept:C1521970,
umls-concept:C1522240,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1709059,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-2-10
|
|
pubmed:abstractText |
Allergen-specific CD4+ Th2 cells play an important role in the immunological processes of allergic asthma. Previously we have shown that, by using the immunodominant epitope OVA323-339, peptide immunotherapy in a murine model of OVA induced allergic asthma, stimulated OVA-specific Th2 cells, and deteriorated airway hyperresponsiveness and eosinophilia. In the present study, we defined four modulatory peptide analogues of OVA323-339 with comparable MHC class II binding affinity. These peptide analogues were used for immunotherapy by s.c. injection in OVA-sensitized mice before OVA challenge. Compared with vehicle-treated mice, treatment with the Th2-skewing wild-type peptide and a Th2-skewing partial agonistic peptide (335N-A) dramatically increased airway eosinophilia upon OVA challenge. In contrast, treatment with a Th1-skewing peptide analogue (336E-A) resulted in a significant decrease in airway eosinophilia and OVA-specific IL-4 and IL-5 production. Our data show for the first time that a Th1-skewing peptide analogue of a dominant allergen epitope can modulate allergen-specific Th2 effector cells in an allergic response in vivo. Furthermore, these data suggest that the use of Th1-skewing peptides instead of wild-type peptide may improve peptide immunotherapy and may contribute to the development of a successful and safe immunotherapy for allergic patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
164
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
580-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10623798-Adjuvants, Immunologic,
pubmed-meshheading:10623798-Amino Acid Sequence,
pubmed-meshheading:10623798-Animals,
pubmed-meshheading:10623798-Asthma,
pubmed-meshheading:10623798-Cell Line,
pubmed-meshheading:10623798-Cytokines,
pubmed-meshheading:10623798-Disease Models, Animal,
pubmed-meshheading:10623798-Flow Cytometry,
pubmed-meshheading:10623798-Hemagglutinin Glycoproteins, Influenza Virus,
pubmed-meshheading:10623798-Immunoglobulins,
pubmed-meshheading:10623798-Immunophenotyping,
pubmed-meshheading:10623798-Injections, Subcutaneous,
pubmed-meshheading:10623798-Interphase,
pubmed-meshheading:10623798-Liposomes,
pubmed-meshheading:10623798-Lymphocyte Activation,
pubmed-meshheading:10623798-Male,
pubmed-meshheading:10623798-Mice,
pubmed-meshheading:10623798-Mice, Inbred BALB C,
pubmed-meshheading:10623798-Molecular Sequence Data,
pubmed-meshheading:10623798-Ovalbumin,
pubmed-meshheading:10623798-Peptide Fragments,
pubmed-meshheading:10623798-Th1 Cells,
pubmed-meshheading:10623798-Th2 Cells
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide.
|
|
pubmed:affiliation |
Institute of Infectious Diseases, Department of Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
